Abstract Details

Title Homocysteine: A Potential Risk Factor for Peripheral Neuropathy

Topic General Neurology

Presentation(s) P15 - Poster Session 15 (12:00 PM-1:00 PM)

Poster/Presentation
Number 6-004

Objective To validate whether an elevated plasma level of homocysteine (eHcy) is associated with peripheral neuropathy (PN).

Background We previously reported that eHcy may serve as a biomarker contributing to the etiology of PN (Luo et al., 2014 & 2016; Shandal and Luo 2016). The present study was undertaken to validate this contention.

Design/Methods Charts of patients with PN or primary headaches (HA, as control) seen from January 1, 2014 to December 31, 2018 were retrospectively reviewed. Diagnostic codes were used in searching for PN (355.9/ICD9 and G62.9/ICD10) and HA (784.0/ICD9 and R51/ICD10). Demographic, clinical, and laboratory data were recorded. Subjects with PN or HA were collected. Patients who were excluded were those with an established diagnosis of PN such as acute or chronic inflammatory demyelination polyneuropathy or PN with identifiable etiologies, other than eHcy, such as trauma, long-standing history of diabetes, kidney, renal diseases, infections or recipients of chemo or radiation therapies; secondary HA such as brain structural changes, infections, recipients of cranial surgical procedures; or absence of laboratory studies.

Results A total of 16,086 charts were initially screened. Subjects, who met the inclusion and exclusion criteria, with PN (n=161 age=60.9±14.4 years; male/female=66/95) and HA (n=41, age=48.3±17.2, M/F=6/35) were studied. Significantly higher levels of homocysteine were observed in PN (15.1±12.2 Ref: <11.4 µmol/L, p=0.02) than in HA (10.6±3.4). No statistically significant differences of other laboratory findings were observed in PN vs. HA, including all normal values of vitamin B12, methylmalonic acid, HbA1C, creatinine, TSH and others. Additionally, the frequency of eHcy was significantly increased (p=0.0002) in PN (51.6%) as compared to that of HA (19.5%).

Conclusions Our study confirmed that the incidence of eHcy is higher in patients with PN than with HA, validating the proposal that eHcy may serve as a biomarker contributing to the etiology of PN.

Authors/Disclosures
Rebecca T. Hsu, MD (Hospital of the University of Pennsyvania) PRESENTER	Dr. Hsu has nothing to disclose.
	No disclosure on file
Anita K. Mehta, MD (Summit Medical Group)	Dr. Mehta has nothing to disclose.
Xiaohong Si, MD (Austin Va outpatient clinic)	Dr. Si has nothing to disclose.
	No disclosure on file
Jin J. Luo, MD, PhD, F�鶹��ýӳ�� (Lewis Katz School of Medicine At Temple University)	Dr. Luo has nothing to disclose.

�鶹��ýӳ��

�鶹��ýӳ��